C4 Therapeutics and Merck KGaA Partner to Discover Protein Degraders Against Oncogenic Proteins
Shots:
- C4 Therapeutics and Merck KGaA have signed a strategic license & collaboration agreement for the discovery of two targeted protein degraders against oncogenic proteins of interest from the former’s internal discovery pipeline
- As per the agreement, C4T will obtain $16M upfront, ~$740M on achieving discovery, regulatory & commercial milestones plus mid-single to low-double-digit tiered future sales-based royalties for each product. C4T’s R&D costs will be covered by Merck KGaA
- Furthermore, C4T’s Torpedo platform will be used for protein degraders’ discovery and Merck KGaA will handle the clinical development & commercialization of the discovered drug candidates
Ref: C4 Therapeutics | Image: C4 Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
